This website collects cookies to deliver better user experience. Cookie Policy
Accept
Sign In
The Wall Street Publication
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Reading: AstraZeneca Submits Preventive Covid-19 Treatment to FDA
Share
The Wall Street PublicationThe Wall Street Publication
Font ResizerAa
Search
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© 2024 The Wall Street Publication. All Rights Reserved.
The Wall Street Publication > Blog > Business > AstraZeneca Submits Preventive Covid-19 Treatment to FDA
Business

AstraZeneca Submits Preventive Covid-19 Treatment to FDA

Editorial Board Published October 5, 2021
Share
AstraZeneca Submits Preventive Covid-19 Treatment to FDA
SHARE

LONDON— AstraZeneca AZN 1.44% PLC said Tuesday it has asked U.S. regulators for emergency-use authorization for an antibody drug that earlier this year showed strong efficacy in preventing symptomatic Covid-19, offering a potential alternative in evading the disease.

AstraZeneca said in August that it would aim the antibody combination, called AZD7442 and delivered as a shot, at preventing Covid-19 symptoms, like a vaccine. The primary use, AstraZeneca said, would be for a minority of people with chronic diseases and other conditions that could render vaccines less effective. Emergency-use authorization from the Food and Drug Administration, if granted, would make the long-acting antibody cocktail a first-of-its kind preventive option.

The company earlier hoped the therapy could be used to treat acute Covid-19 symptoms and stem infection to keep people already exposed to the virus out of the hospital. But the drug failed in late-stage trials for that primary purpose, in a setback for AstraZeneca.

The antibody treatment is separate from AstraZeneca’s widely used Covid-19 vaccine developed in partnership with the University of Oxford.

The company in August said AZD7442 showed 77% efficacy in reducing risk of symptomatic Covid-19 compared with a placebo in late-stage clinical trials testing its usefulness as a preventive treatment. In summarized preliminary findings, the company said that more than three-fourths of the 5,197 participants in the trial had comorbidities, or chronic disease, including conditions that could render vaccines less effective.

AstraZeneca executives and the principal trial investigator said in August the primary target for the antibody will be people who take Covid-19 vaccines but don’t get the hoped-for immune boost because of these preconditions. It could also be used by people who have been advised not to take the vaccine—for instance, those at risk of allergic reactions—or as an extra precaution for fully vaccinated people.

The drug is injected into the muscle like existing vaccines, but in two shots given at the same time rather than spaced out, according to an AstraZeneca spokeswoman. It was well-tolerated and safe, the company said.

Full trial results haven’t yet been published or reviewed by independent researchers. AstraZeneca has said laboratory tests suggest the drug is effective against the highly transmissible Delta variant.

“With this first global regulatory filing, we are one step closer to providing an additional option to help protect against Covid-19 alongside vaccines,” AstraZeneca’s Mene Pangalos, a senior biopharmaceuticals-development executive, said in Tuesday’s statement.

The company said on Tuesday it is in discussions with the U.S. and other governments about potential supply deals. Earlier in the pandemic, the drugmaker received funding pledges that could exceed $700 million from the U.S. government to develop, test and potentially supply up to 700,000 doses of AZD7442 this year. The antibodies used were developed by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020.

Doctors are increasingly turning to monoclonal-antibody drugs to treat high-risk patients who get sick with Covid-19. WSJ takes a look at how the therapies work and why they’re important for saving lives. Illustration: Jacob Reynolds/WSJ

Health experts say widespread access to cheap Covid-19 vaccines, relative to the high cost of antibody drugs, will likely limit the market for AZD7442 as a preventive tool. But in a subset of people whose immune systems don’t respond well to vaccines, the antibody cocktail could provide a new, additional option to prevent symptomatic Covid-19.

Covid-19 vaccines were brought to market at remarkably fast speeds, but antibody treatments and other reliable therapeutics have been slower, with more mixed results. Global surges in Delta cases led hospitals to turn to antibody drugs to prevent overcapacity. Monoclonal antibody drugs are designed to mimic natural antibodies produced by the immune system to fight the coronavirus.

The U.K., Europe and the U.S. already have approved use of a monoclonal-antibody treatment from Regeneron Pharmaceuticals Inc. and Roche Holding AG . Last week, another new post-exposure Covid-19 treatment showed promise in a pivotal study at preventing high-risk people from becoming seriously ill or dying—an experimental pill from Merck & Co. and its partner Ridgeback Biotherapeutics LP. The promising trial results could mean the drug, called molnupiravir, potentially could provide doctors a new option for at-home treatment of Covid-19 in infected people.

AstraZeneca said that in addition to the request for authorization of AZD7442 as a preventive drug, it also continues to test it for potential use as a primarily outpatient treatment for people already exposed to Covid-19 and with mild to moderate cases.

Write to Jenny Strasburg at jenny.strasburg@wsj.com

Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

TAGGED:Business NewsPAIDWall Street Publication
Share This Article
Twitter Email Copy Link Print
Previous Article Singapore Set to Increase Control Over Online Content Singapore Set to Increase Control Over Online Content
Next Article Bitcoin Price Passes ,000: What to Watch When the Stock Market Opens Today Bitcoin Price Passes $50,000: What to Watch When the Stock Market Opens Today

Editor's Pick

TLI Ranked Highest-Rated 3PL on Google Reviews

TLI Ranked Highest-Rated 3PL on Google Reviews

EXTON, PA — Translogistics, Inc. (TLI), a trailblazer in the 3PL and managed logistics space since its founding in 1994,…

By Editorial Board 12 Min Read
David Villar’s time with SF Giants doubtless nearing an finish after second DFA
David Villar’s time with SF Giants doubtless nearing an finish after second DFA

SAN FRANCISCO — As soon as heralded because the Giants’ third baseman…

6 Min Read
Meet the Preakness Stakes horses working within the 2025 race
Meet the Preakness Stakes horses working within the 2025 race

The Preakness Stakes has a area of 9 horses set to race…

8 Min Read

Oponion

10 Greatest Swimsuit Equipment For Males – Full The Look in 2025 | Fashion

10 Greatest Swimsuit Equipment For Males – Full The Look in 2025 | Fashion

We independently consider all really helpful services. Any services or…

May 10, 2025

U.S. scrambles for bases in central Asia after Afghanistan withdrawal

President Biden is racing to find…

November 8, 2021

Valkyries erase double-digit deficit, shut preseason with win over Phoenix Mercury

Sunday’s recreation towards the Phoenix Mercury…

May 12, 2025

Biden scolds ‘extreme’ Republicans for lack of bipartisanship in first late-night TV appearance

President Biden steered clear of jokes…

December 11, 2021

Stock Futures Creep Up Ahead of Tech Earnings

U.S. stock futures edged up ahead…

October 25, 2021

You Might Also Like

Joseph Safina’s Vision for Empowered Entrepreneurship in the Age of AI and Acquisitions
BusinessTrending

Joseph Safina’s Vision for Empowered Entrepreneurship in the Age of AI and Acquisitions

In an era where ChatGPT can write marketing plans, and billion-dollar startups are snapped up before their founders can print…

6 Min Read
How Good Agriculture Can Make the most of a Satellite tv for pc API for Earth Commentary
Business

How Good Agriculture Can Make the most of a Satellite tv for pc API for Earth Commentary

The agricultural sector is present process a seismic shift, induced by the fusion of digital applied sciences like IoT, AI,…

9 Min Read
Soracom and Marubeni Announce Strategic IoT Collaboration and Conform to Set up Joint Enterprise
Business

Soracom and Marubeni Announce Strategic IoT Collaboration and Conform to Set up Joint Enterprise

New group will assist IoT MVNO capabilities in Japan and past Soracom, Inc., a world IoT platform supplier with full…

3 Min Read
Semtech Strengthens International IoT Connectivity Safety with AI-enabled Community Operations
Business

Semtech Strengthens International IoT Connectivity Safety with AI-enabled Community Operations

Actual-time Menace Detection Delivers 99.95% Uptime in 2024 Whereas Stopping Fraud Throughout Related Gadgets Semtech Company, a number one supplier…

2 Min Read
The Wall Street Publication

About Us

The Wall Street Publication, a distinguished part of the Enspirers News Group, stands as a beacon of excellence in journalism. Committed to delivering unfiltered global news, we pride ourselves on our trusted coverage of Politics, Business, Technology, and more.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Term of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices

© 2024 The Wall Street Publication. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?